Gefitinib EGFR inhibitor Non-small cell lung cancer Rash & diarrhea.

Slides:

Advertisements

Similar presentations

Cytidine analogue ALL, AML

Advertisements

 LV dysfunction  Vasospasm and ischemia  Hypertension  VTE  Conduction disease  Arrhythmias.

Presenters: Maria Maqsood ξ Sania Munir Cancer Immunotherapy.

Pancreatic NET What’s new? George Fisher, MD PhD Pamela Kunz, MD Division of Oncology Stanford University Medical School March 29, 2009.

 Encompass how some hormones and antihormones are utilized as anticancer therapy  Identify concept of immunomodulation as an anticancer treatment modality.

Also known as lymphoplasmacytic lymphoma A rare type of non-Hodgkin lymphoma WM affects lymphoplasmacytic (LPL) Cells B-Cells LPL Cells Plasma Cells Abs.

Approaching Personalized Oncology as a Clinician and Researcher Where are we now, and how can we take it further? Andrew Poklepovic MD Massey Cancer Center.

Adaptive Population Enrichment for Oncology Trials with Time to Event Endpoints Cyrus Mehta, Ph.D. President, Cytel Inc.

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.

Figure 16.45a The Biology of Cancer (© Garland Science 2007)

Nitrogen mustards: mustard gas used first during WWI. Leukopenia and GI ulceration noted in survivors Bondage: crosslinking agents.

HEPATOCELLULAR CARCINOMA Manal Abdel Hamid Associate Prof. Of medical oncology.

Targeted Therapy for Renal Cell Cancer Dr.MahmoodzadehOncologist-Hematologist.

Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.

New Technologies and Challenges Targeted Therapies in Cancer New Technologies and Challenges Targeted Therapies in Cancer Ian Olver MD PhD CEO The Cancer.

Biological and Molecular Targeted Therapy for HHC

Biotechnology in Fighting Fatal Disease – Cancer National Biotechnology Symposium 2012 Innovations in Biotechnology: From Education to Industry Sep 1,

Special Topics Cancer Pharmacology II Joseph De Soto MD, PhD, FAIC.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

NEW WEAPONS IN THE WAR OF CANCER Lodovico Balducci M.D. H. Lee Moffitt Cancer Center Tampa, Florida.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Hormonal Agents Estrogen & Androgen Inhibitors Gonadotropin-Releasing Hormone Agonists Aromatase Inhibitors Tamoxifen Leuprolide Aminogluthethimide.

Presented by : PharmD Group 5 Supervised by : Dr. Nashaat Lotfy.

DNA diagnosis of lung cancer

Targeted Therapies - little & large explained Chris Clarke Macmillan Lead Pharmacist LNR Cancer Network.

Cancer, Oncogenes and Tumour suppressor Genes 1 Dr. Mohamed M. Sayed-Ahmed.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 102 Anticancer Drugs II: Hormonal Agents, Biologic Response.

A daganat-terápia alapjai Diagnosis –Histopathology –Tumor markers Cell surface markers (CD20, CD34…) Genetic markers (BRCA-1,Philadelphia chromosome)

Targeted Therapy in Hematology Dieter Hoelzer – Frankfurt am Main Christoph Zielinski – Vienna, Austria Hans-Joachim Schmoll – Halle, Germany Richard Greil.

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

CANCER, ONCOGENES AND TUMOUR SUPPRESSOR GENES PHL 425 Dr. Mohamed M. Sayed-Ahmed 1/1/2015.

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

Tyrosine Kinase Inhibitors PHL 425 Dr. Mohamed M. Sayed-AShmed.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

Growth Factors, Receptors,

In humans, billions of cells die each day Cells die in two ways: 1.Necrosis 2.Apoptosis.

Chapter Plant products 抗肿瘤植物药. Chapter Plant products Paclitaxel (Taxol) 紫杉醇.

ANTICANCER DRUGS DR FATAI OLUYADI USMLEINCLINED.COM 1.

Basic Science of Surgical Oncology

Anticancer drugs Specific tumor-targeted therapy, Immunomodulators, Anticancer Vaccines.

Therapy Targeted د. نورس نبيل جعفر أخصائية في علم الأورام طبيبة مشرفة بمشفى ابن النفيس مؤتمر نقابة أطباء سورية العلمي الأول.

TARGETED CANCER THERAPY IN 2016: WHAT THE PRACTICING PATHOLOGIST OR ONCOLOGIST NEEDS TO KNOW (SUPPLEMENTARY SLIDES) Steven J. Kussick, MD, PhD Associate.

From the Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston; and the Department of Internal Medicine III, University.

GENE EXPRESSION PROFILING IN BREAST CARCINOMA Dr Partha Ghosh 2 nd year PGT, General Surgery N.R.S Medical college.

Sarah Cannon Research Institute ASCO Presentation Summary.

PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.

¿Qué ver en ASCO 2017?.

Supplementary Figure 1. Importance of first neighbours in breast cancer, hepatocellular carcinoma and non-small cell lung cancer in the SignaLink network.

Tyrosine Kinase Inhibitors PHL 425

Wijendra Senarathne1, Peggy Gates1, Semir Vranic2, Zoran Gatalica1

Tyrosine Kinase Inhibitors PHL 417

Antineoplastic Prescribing II

Best-Selling Cancer Drugs,

Anti-cancer treatment טיפול בסרטן

Discussion Outline Cells of the Immune System.

Volume 9, Issue 6, Pages (June 2006)

Spectral Karyotyping Immune system.

Renée van Amerongen, Anton Berns Cancer Cell

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 9, Issue 6, Pages (June 2006)

ANTIMETABOLITES Antimetabolites are structurally related to normal compounds that exist within the cell They generally interfere with the availability.

IMITAB® (Imatinib Mesylate BP Tablets)

ADCC by T lymphocytes after transfection.

Esteller, New England Journal of Medicine, 2008

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Tyrosine kinase inhibitors

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Presentation transcript:

gefitinib EGFR inhibitor Non-small cell lung cancer Rash & diarrhea

erlotinib EGFR inhibitor non-small cell lung cancer & pancreatic carcinoma (better than gefitinib) Rash& diarrhea

Cetuximab EGFR antibody Colorectal cancer & head and neck cancer Rash & diarrhea

trastuzumab (aka herceptin) EGFR antibody Breast cancer or metastatic gastric cancer w/HER2 expression cardiotoxicity

imatinib Inhibitor of BCR-ABL, C-KIT, and PDGFR CML, GI stromal tumor expressing KIT, idiopathic hypereosinophilic syndrome

Sorafenib Inhibitor of B-RAF Renal cell carcinoma & hepatocellular carcinoma

Rapamycin (sirolimus) mTOR inhibitor Rejection prophylaxis for renal transplant

Bortezomib Inhibits 20S subunit of proteasome Multiple myeloma & mantle cell lymphoma

Bevacizumab VEGF/VEGFR antibody Metastatic colorectal cancer & NSCLC Contraindicated for cerebrally metastasized NSCLC

sunitinib VEGF/VEGFR inhibitor Renal cell carcinoma & GI stromal tumor

thalidomide Inhibits TNF-a and bFGF Multiple myeloma & erythema nodosum leprosum Beware thrombosis

lenalidomide Inhibits TNF-a and bFGF (better than thal.) Multiple myeloma & myelodysplastic syndrome Lesser risk of thrombosis than thalidomide

rituximab CD-20 antibody B cell non-hodgkin lymphoma Beware immunosuppression